Terry Rosen, Ph.D. (CEO)

Terry has been leading successful drug discovery and development organizations in the biotechnology and pharmaceutical industries for over 30 years. In 2015, he co-founded Arcus Biosciences, a drug discovery company focused on the treatment of cancer by blocking tumor-induced immunosuppression. Previously, he was co-founder and CEO of Flexus Biosciences, a company created to develop small-molecule drugs to reverse tumor immunosuppression, which was acquired by Bristol-Myers Squibb early in 2015 for $1.25 billion. Prior to Flexus, Terry served as Vice President, Therapeutic Discovery (TD) at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. He was named Amgen Washington site head in 2006, transitioned to a leadership role heading Chemistry Research and Discovery in 2007 and became the head of Protein Sciences in 2011. He and his leadership team were responsible for the creation of the TD organization, a group of 550+ staff responsible for all of Amgen’s large and small molecule drug discovery efforts.

Prior to joining Amgen, Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. Terry serves on the Salk Institute Board of Trustees, the leadership committees of the University of Michigan Undergraduate Research Opportunity Program and Life Sciences Institute, the Berkeley Chemistry Advisory Board, the Caltech Biology & Bioengineering Chair’s Council and the Board of the California Life Sciences Association.​

Juan Jaen, Ph.D. (President)

Juan has been engaged in all aspects of drug discovery and development for more than 30 years. In 2015, he co-founded Arcus Biosciences together with Terry Rosen. Prior to that, he was co-founder and President/Head of R&D at Flexus Biosciences, until its acquisition by Bristol-Myers Squibb for $1.25 billion. Previously, he was Chief Scientific Officer and Senior Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Juan led the discovery and progression into the clinic of 8 novel drug candidates in the immunology space. At ChemoCentryx, Juan led the discovery efforts for the multi-year collaboration with GSK, which generated over $100M in non-dilutive milestones and fees. From 1996 to 2006, Juan held various scientific management positions at Tularik (responsible for about 100 scientists in Medicinal and Computational Chemistry, as well as Structural Biology) and then Amgen Inc. (after its acquisition of Tularik in 2004), most recently as Vice President of Chemistry.

From 1983 to 1996, Juan held various scientific leadership positions at Parke-Davis/Warner-Lambert. Juan holds a Visiting Scholar appointment (ChEM-H) at Stanford University and is a member of the Scientific Advisory Board at Cleave Biosciences. Juan obtained a B.S. degree in Chemistry from Universidad Complutense in Madrid (Spain) and a Ph.D. degree in Organic Chemistry from the University of Michigan. He has co-authored over 100 scientific papers and is an inventor on 50 issued U.S. patents. Juan has been responsible for the advancement of over 20 novel molecules into clinical development for diseases including cancer, Alzheimer’s, Crohn’s, RA, diabetes and diabetic nephropathy, psoriasis, asthma, and vasculitis, among others.

Jennifer Jarrett, M.B.A.
(Chief Business and Financial Officer)

Ms. Jarrett most recently served as Chief Financial Officer of Medivation, where she was responsible for finance, accounting, information technology, investor relations, strategy and business development.

Prior to Medivation, Jennifer spent 20 years in investment banking, most of that time covering biotechnology companies. Most recently, Ms. Jarrett served as a Managing Director at Citigroup where she headed up their west coast life sciences investment banking group. Prior to Citigroup, Ms. Jarrett worked in the investment banking divisions of Credit Suisse, Donaldson, Lufkin & Jenrette, Merrill Lynch and Kidder Peabody. Jennifer currently serves on the Board of Directors of Audentes Therapeutics. Jennifer received her M.B.A from the Stanford Graduate School of Business and her undergraduate degree in Economics from Dartmouth College.

Jay Powers, Ph.D. (VP, Drug Discovery)

Jay has had a remarkable track record of success in drug discovery in the biopharmaceutical industry, spanning a period of nearly 20 years. Most recently, Jay was Vice President of Drug Discovery at Flexus Biosciences and then FLX Bio. During his tenure at Flexus, he oversaw drug design efforts in the IDO Inhibitor program, which was the main driver for the company’s acquisition by BMS in early 2015. Previously, he was Vice President of Drug Discovery at ChemoCentryx. During his tenure there of just under 7 years, Jay was involved in the discovery and clinical progression of 7 novel drug candidates in the immunology area, the most advanced of which is currently undergoing Phase 3 evaluation in ANCA-associated renal vasculitis. Prior to joining ChemoCentryx in 2007, Jay was at Tularik and then Amgen (after its acquisition of Tularik in 2004), most recently as Scientific Director in Medicinal Chemistry. Jay began his career in 1996, working in the anti-infectives area at Abbott Laboratories.

Jay received a B.S. degree in Biochemistry and a Ph.D. in Organic Chemistry from the University of Minnesota and completed postdoctoral studies in the laboratories of Professor Gilbert Stork at Columbia University. Jay is an inventor on over 50 issued U.S. patents and has published extensively in the areas of medicinal and synthetic organic chemistry. Over the course of his career, Jay has been responsible for the discovery of 16 compounds that have gone into clinical development in the oncology, immunomodulation, inflammation, antiviral and metabolic disease areas.

Joyson Karakunnel, MD, MSc, FACP.
(VP, Clinical Development)

Joyson Karakunnel is an experienced medical oncologist and hematologist with drug development expertise both in academics and industry. In addition to his role at Arcus, he is also an advisor to the Parker Institute for Cancer Immunotherapy. Prior to joining industry, he was an investigator in clinical trials at the NCI and team leader for the hematologic group at Walter Reed National Military Medical Center. Prior to joining Arcus, he was at AZ/Medimmune and lead some of the key phase 1/1b clinical trials with immunomodulators including durvalumab and tremelimumab both as single agents and in combination in solid tumors and hematologic malignancies which supported the development of phase 3 randomized trials in multiple indications. While at AZ/Medimmune, he was the early phase clinical lead for BLA submissions in lung cancer and the program lead for other immunomodulators including agonists. He was the lead for programs at Medimmune with external partners such as Celgene and Innate. He was an Associate Professor at the Uniformed Services University of the Health Sciences and medical reviewer at the FDA.

Joyson continues to treat patients in clinical practice. He completed his medical training at Annamalai University in India, internal medicine residency at Overlook Hospital/UMDNJ where he was chief resident and completed fellowships in Hematology, Oncology and Pain and Palliative Care at the National Cancer Institute. He holds a Masters in pharmacology from the University of Maryland and is a member of Phi Beta Kappa. He was elected to be a Fellow in the American College of Physicians. Joyson has been a co-author on several papers, book chapters and given several invited oral presentations at conferences and academic centers.

Joyson Karakunnel

Ulrike Schindler, Ph.D. (VP, Biology)

Uli has spent more than 20 years in the biopharmaceutical industry and has led research organizations in the U.S. and Germany. In her most recent industry position, until 2013 Uli led the Biologics Discovery function at Amgen, a group of about 200 FTE which was responsible for all of Amgen’s large-molecule drug discovery efforts. In 2000, Uli established and led the Regensburg (Germany) technology site for Tularik, which was acquired by Amgen in 2004. She and her team were responsible for all small-molecule high-throughput screens for Tularik and subsequently Amgen. During this time, the team identified small-molecule leads for numerous drug targets involved in various therapeutic indications such as cancer, asthma, allergy, metabolic disorders and neurological diseases. Concurrently with her assignment in Regensburg, Uli also led Amgen’s Alantos Pharmaceutical AG in Heidelberg (Germany), a specialized team of medicinal chemists.

Prior to Amgen, Uli held various positions at Tularik, where she established and led various Immune Disorders projects between 1993 and 2000. Uli obtained her Ph.D. degree in Biology from the University of Freiburg (Germany) in 1992. From 1987 to 1993, she was a visiting scientist at the University of Pennsylvania, where she focused her research on the regulation of gene transcription. Uli has co-authored over 40 scientific publications and book chapters.

Steve Young, Ph.D. (VP, Technology)

Steve has been in scientific, technical and leadership roles across Europe and the US since 1993, most recently as VP of Technology at Flexus Biosciences (subsequently FLX Bio). He was the first scientist at Flexus and spearheaded a ground-up build of the biology and IT/informatics functions, including hiring the team and establishing the SAR data infrastructure which enabled the successful IDO inhibitor program. Previously, as Executive Director at Amgen, heading the Discovery Technologies Department, Steve led a group of 110 scientists across five geographical sites to enact key technical functions including Research Automation and Technology, Materials Management, HTS, Bioassay Technology and Target Discovery/Validation. Steve started at Amgen in 2004, following the acquisition of Tularik, where he had been leading the Lead Discovery Function (Small Molecule and Genomic Screening, Automation and SAR data generation). He moved to Seattle to establish the first automated screening laboratory at Amgen, Washington in 2006.

In 2008 he moved again to Massachusetts to serve as the inaugural site head at Amgen’s east coast research hub in Cambridge, focusing on Amgen’s growth in a key scientific locale and acting as Amgen’s senior representative for academia, industry and government affairs. Prior to moving to the U.S. in 2001, Steve headed the HTS Department at Roche U.K., having started his career earlier at Glaxo. Steve holds B.Sc. (Hons) and Ph.D. degrees in Biochemistry from the University of Bristol and a diploma in Business Administration from the Open University. He is currently on the Board of Directors of the Society for Laboratory Automation and Screening.

Nigel Walker, Ph.D. (VP, Protein Science)

Nigel maintains a passion for drug discovery and has more than 30 years of experience in the pharmaceutical, biotechnology and chemical industries. Prior to joining Arcus, Nigel was the Executive Director of Amgen’s Molecular Structure & Characterization division leading 80+ staff engaged in providing analytical & biophysical support for all of Amgen’s large and small molecule drug discovery programs. Throughout his career, Nigel has repeatedly utilized 3D structural data in support of drug discovery projects; he directed Amgen’s structural analysis of the binding modes of antibody inhibitors of PCSK9, including the marketed product Repatha™ (evolocumab) for the treatment of hypercholesterolemia. Nigel joined Tularik in 1998 as Director of Structural Biology and established structural biology and computational chemistry groups to support a diverse array of small molecule drug discovery projects. In 2004, he transitioned to Amgen following their acquisition of Tularik.

Nigel started his industrial career in 1985 at BASF AG in Germany. As their first protein crystallographer, Nigel built their facility and drove the research to produce key first-in-class 3D structures for proteins such as TNF-alpha and caspase-1. Over the course of his career, Nigel has worked on a broad portfolio of molecular targets with a variety of therapeutic modalities and is a co-author on over 100 peer reviewed articles and a co-inventor on 15 issued U.S. patents. Nigel holds B.Sc. (Hons) and Ph.D. degrees in Biochemistry from the University of Bristol, U.K.

Andrew Pennell, Ph.D. (VP, Preclinical Development)

Andrew has been involved in all aspects of drug discovery and development in pharmaceutical and biotechnology companies in the U.S. and U.K. for more than 20 years, establishing medicinal chemistry and preclinical development departments and leading discovery and preclinical development teams in a variety of therapeutic areas (e.g., oncology, autoimmune, inflammatory, bacterial, viral, cardiovascular, metabolic and CNS diseases). Prior to joining Arcus, Andrew was Executive Director of Preclinical Development and, before that, Director of Medicinal Chemistry at ChemoCentryx, where he was centrally involved in the discovery and clinical development of nine novel drug candidates, several of which completed Phase 2 trials and two of which have entered Phase 3 development. Between 1993 and 2002, Andrew held various scientific management positions, first at GlaxoWelcome and then as Director of Medicinal Chemistry at Genesoft Inc.

Andrew’s responsibilities have included leadership of medicinal chemistry, DMPK, preclinical safety evaluation and chemistry / pharmaceutical development (CMC)Andrew holds a B.Sc. (Hons) degree in Chemistry and a Ph.D degree in Organic Chemistry from Imperial College London and conducted postdoctoral research at Columbia University under the guidance of Professor Gilbert Stork.  Andrew is an inventor on more than 50 issued U.S. patents.

Tim Sullivan, Ph.D. (VP, Business Development)

Tim has been involved in multiple aspects of drug discovery and development in pharmaceutical and biotechnology companies in the U.S. for more than 15 years, leading discovery and pharmacology teams in a variety of therapeutic areas (e.g., oncology, autoimmune, inflammatory, metabolic and CNS diseases) as well as being involved in groups focused on the external identification of novel technologies and assets suitable for in-licensing and/or acquisition. Prior to joining Arcus, Tim was a Senior Director in the External R&D Innovation (ERDI) group at Pfizer where he focused on identifying new Immuno-Oncology opportunities across all therapeutic modalities, as well as managing the global alliances with Servier and Cellectis focused on the discovery and development of allogeneic CAR-T cell products. Before Pfizer, Tim was a Director in the New Frontier Science group at Takeda, where he primarily focused on identifying and funding very early-stage technologies being developed in academic settings to determine utility in accelerating drug discovery and development.

Prior to Takeda, Tim held various scientific management roles, first at Tularik/Amgen and then as Director of Biology at ChemoCentryx. Tim holds a B.A. degree from the University of Notre Dame and a Ph.D. degree in Cellular and Molecular Biology from the University of California, Berkeley where he trained in the laboratory of Dr. James Allison.

Steven Chan (VP Finance)

Steve is a seasoned financial executive with over 20 years of experience managing the finance and accounting functions at companies in varying stages of growth, including two start-ups that had successful IPOs. Prior to joining Arcus, Steve was the VP Finance, Corporate Controller for MyoKardia, Inc. where he helped lead the company public in 2015 and built out the finance and accounting infrastructure and teams. Before MyoKardia, Steve was at Solta Medical, Inc., a global medical device company, where he was a Vice President and Corporate Controller, responsible for leading day-to-day company-wide accounting and finance operations from 2010 to 2014 until it was sold to Valeant Pharmaceuticals. Prior to Solta Medical, Steve was Vice President, Finance at Moody’s Analytics Inc. from 2007 to 2010, where he focused heavily on international expansion and M&A activities in addition to leading a 25 person finance team, Worldwide Revenue Director at Polycom from 2006 to 2007, and a Regional Controller at Logitech International S.A. from 2002 to 2006.

Steve started his career at KPMG LLP, is a Certified Public Accountant in California (inactive status) and holds a B.S. in Business Administration from the Haas School of Business at the University of California, Berkeley.